公司資料
89bio, Inc. 股價、新聞與催化劑
- 股票代碼:
- ETNB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for ETNB.
公司概覽
業務概覽
89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, 89bio sits in specialty biopharma.
商業模式特徵
The business depends on clinical data, dose strategy, and whether the company can deliver a differentiated MASH profile.
生技產業定位
89bio is one of the more closely watched liver-disease names because efficacy and safety can quickly change the story.
未來催化劑
- 89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。